Indraprastha Medical Corporation Limited (Indramedco) (NSE: INDRAMEDCO, BSE: 532150) is a New Delhi, Delhi-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹3,102 Cr, it ranks #1,040 by market cap among the 6,197 Indian listed companies on FinBizNet, and #18 of 46 in Hospitals and Healthcare Centers. At ₹330.65 (as of 16 Nov 2026), the share price is 40.2% below its 52-week high of ₹553.15 and 12.6% above its 52-week low of ₹293.65. The share price is down 46.7% over one year and down 11.2% over three months.
| Current Price | ₹330.65 |
|---|---|
| Market Cap | ₹3,102 Cr |
| NSE Symbol | INDRAMEDCO |
| BSE Code | 532150 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 16.8 |
| Return on Equity | 27.47% |
| Return on Assets | 15.18% |
| 52-Week Range | ₹293.65 – ₹553.15 |
| 1-Year Price Change | -46.7% |
| 3-Month Price Change | -11.2% |
| Beta (1Y) | 0.45 |
| Dividend Yield | 1.19% |
| Headquarters | New Delhi, Delhi |
| Website | www.apollohospitals.com/delhi/ |
| Revenue | ₹413 Cr |
|---|---|
| Net Profit | ₹54 Cr |
| Net Margin | 13.0% |
| EPS (Basic) | ₹5.84 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indraprastha Medical Corporation Limited (Indramedco) reported revenue of ₹413 Cr in Q2 FY27, up 8.4% from ₹381 Cr in Q2 FY26 and up 1.6% from ₹406 Cr in Q1 FY27. It posted a net profit of ₹54 Cr for the quarter, against a net profit of ₹49 Cr in Q2 FY26 (up 8.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹334 Cr (Q4 FY25) to ₹413 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹413 Cr | ₹54 Cr | 13.0% |
| Q1 FY27 | ₹406 Cr | ₹56 Cr | 13.8% |
| Q4 FY26 | ₹365 Cr | ₹42 Cr | 11.4% |
| Q3 FY26 | ₹372 Cr | ₹41 Cr | 11.0% |
| Q2 FY26 | ₹381 Cr | ₹49 Cr | 13.0% |
| Q1 FY26 | ₹365 Cr | ₹51 Cr | 14.1% |
| Q4 FY25 | ₹334 Cr | ₹41 Cr | 12.3% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 51.00% of Indraprastha Medical Corporation Limited (Indramedco)'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 56.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive med
1. Healthcare-This segment provides hospital services.
1. Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Indraprastha Medical Corporation Limited (Indramedco) | ₹3,102 Cr | 16.8 | 27.47% | ₹413 Cr | -46.7% |
Listed by market capitalisation. Ratios are shown for context only.
Indraprastha Medical Corporation Limited (Indramedco) is trading at ₹330.65, with a market capitalisation of ₹3,102 Cr.
Indraprastha Medical Corporation Limited (Indramedco) operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Indraprastha Medical Corporation Limited (Indramedco) has a P/E of 16.8 and a return on equity of 27.47%.
Indraprastha Medical Corporation Limited (Indramedco) is listed on the NSE under the symbol INDRAMEDCO and on the BSE under the scrip code 532150.
Indraprastha Medical Corporation Limited (Indramedco)'s share price is down 46.7% over one year and down 11.2% over three months. Its 52-week range is ₹293.65 to ₹553.15.
In Q2 FY27, Indraprastha Medical Corporation Limited (Indramedco) reported revenue of ₹413 Cr and net profit of ₹54 Cr, with basic EPS of ₹5.84 (standalone, parsed from the company's exchange filing).
Indraprastha Medical Corporation Limited (Indramedco) reported revenue of ₹413 Cr in Q2 FY27, up 8.4% from ₹381 Cr in Q2 FY26 and up 1.6% from ₹406 Cr in Q1 FY27.
Promoters held 51.00% of Indraprastha Medical Corporation Limited (Indramedco)'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.